Follow the Akari Therapeutics Plc share price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €15.4m. The latest transaction was filed on 19 August 2026 (Attribution). Among the most active insiders: Patel Samir Rashmikant. The full history is openly available.
49
Insider Decl.
n/a
Thresholds
€35,128
4 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Akari Therapeutics Plc Strong Buy (bullish), based on 2 analysts. Average price target: US$28.50.
33Σ signal
Buys €35,128n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
446,428 shares@ US$1.1222.7% of flowAmerican Depositary Shares representing Ordinary SharesSEC:0000950170-25-036487:0
25 of 49 declarations
About Akari Therapeutics Plc
Akari Therapeutics Plc is a biopharmaceutical company focused on developing treatments for autoimmune diseases and inflammatory disorders. It is listed on NASDAQ under the ticker symbol AKTX.